Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -3% Improvement Relative Risk Ventilation -3% ICU admission -4% Formiga et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? PSM retrospective 20,641 patients in the USA (Mar 2020 - May 2021) No significant difference in outcomes seen Formiga et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02870-1 Favors aspirin Favors control
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
Formiga et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02870-1
Formiga et al., Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from.., Internal and Emergency Medicine, doi:10.1007/s11739-021-02870-1
Nov 2020   Source   PDF  
  All Studies   Meta
Retrospective 20,641 hospitalized patients in Spain, showing no significant difference in outcomes with existing aspirin use.
risk of death, 3.4% higher, RR 1.03, p = 0.48, treatment 1,000 of 3,291 (30.4%), control 874 of 2,885 (30.3%), odds ratio converted to relative risk, propensity score matching.
risk of mechanical ventilation, 3.2% higher, RR 1.03, p = 0.75, treatment 213 of 3,291 (6.5%), control 181 of 2,885 (6.3%), propensity score matching.
risk of ICU admission, 4.2% higher, RR 1.04, p = 0.65, treatment 283 of 3,291 (8.6%), control 238 of 2,885 (8.2%), propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Formiga et al., 29 Nov 2020, retrospective, USA, peer-reviewed, 24 authors, study period 1 March, 2020 - 1 May, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Internal and Emergency Medicine (2022) 17:761–775 IM - ORIGINAL Does admission acetylsalicylic acid uptake in hospitalized COVID‑19 patients have a protective role? Data from the Spanish SEMI‑COVID‑19 Registry Francesc Formiga1 · Manuel Rubio‑Rivas1 · José María Mora‑Luján1 · Samara Campos Escudero2 · Rosa Fernandez Madera Martinez3 · Manuel Mendez‑Bailón4 · Pedro Durán‑del Campo5 · Andrea Riaño Pérez6 · Francisco‑Javier García‑Sánchez7 · José Nicolás Alcalá‑Pedrajas8 · Sergio Arnedo Hernández9 · Almudena Hernández Milian10 · Ana Latorre Díez11 · Ricardo Gil Sánchez12 · Ramon Boixeda13 · Julio Vicente14 · Begoña Cortes15 · Carmen Mella Pérez16 · María Esther Guisado Espartero17 · José López Castro18 · Santiago Rodríguez Suárez19 · Jose F. Varona20 · Ricardo Gomez‑Huelgas21 · Jose Manuel Ramos‑Rincón22 · on behalf of the SEMI-COVID-19 SEMI-COVID-19 Network Received: 24 June 2021 / Accepted: 4 October 2021 / Published online: 29 November 2021 © Società Italiana di Medicina Interna (SIMI) 2021 Abstract Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients. Keywords Acetylsalicylic acid · Coronavirus · COVID-19 · Mortality
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop